- Home
- RLMD
as 11-24-2025 3:41pm EST
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | CORAL GABLES |
| Market Cap: | 289.7M | IPO Year: | N/A |
| Target Price: | $5.50 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.24 - $5.12 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Relmada Therapeutics Inc. (RLMD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kelly Paul Edward | RLMD | Chief Operating Officer | Nov 5 '25 | Buy | $2.20 | 90,000 | $198,000.00 | 502,295 | |
| TRAVERSA SERGIO | RLMD | Chief Executive Officer | Nov 5 '25 | Buy | $2.20 | 272,500 | $599,500.00 | 1,272,500 | |
| Ence Chuck | RLMD | CAO and COO | Nov 5 '25 | Buy | $2.20 | 136,000 | $299,200.00 | 403,931 | |
| Shenouda Maged | RLMD | Chief Financial Officer | Nov 5 '25 | Buy | $2.20 | 500,000 | $1,100,000.00 | 788,335 | |
| TRAVERSA SERGIO | RLMD | Chief Executive Officer | Aug 28 '25 | Buy | $0.74 | 55,976 | $41,422.24 | 1,272,500 | |
| TRAVERSA SERGIO | RLMD | Chief Executive Officer | Aug 27 '25 | Buy | $0.67 | 129,455 | $86,734.85 | 1,272,500 |
Latest Relmada Therapeutics Inc. News
RLMD Breaking Stock News: Dive into RLMD Ticker-Specific Updates for Smart Investing
Barchart
5 days ago
This Stock Is Up 704% in 2025 But Has No Products to Its Name
GuruFocus.com
11 days ago
Relmada Therapeutics Inc (RLMD) Q3 2025 Earnings Call Highlights: Strategic Advances and ...
Motley Fool
12 days ago
Relmada (RLMD) Q3 2025 Earnings Call Transcript
GlobeNewswire
12 days ago
Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates
Money Digest
16 days ago
When Your Investable Assets Reach This Number, It's Time To Hire A Financial Planner
CNW Group
16 days ago
Marriott International Announces Termination of Agreement with Sonder
GOBankingRates
16 days ago
Ways Trump Can Control Mortgage Rates
GOBankingRates
16 days ago
6 Things the 1% Are Doing With Their Roth Accounts (And Why You Should Pay Attention)
Compare RLMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RLMD Relmada Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.